Erasca, Inc., the biotech firm with a mission "to erase cancer" by tackling its biological drivers, has secured $550.0M in new funding. The company, which has assembled a proven team and collaborates with world-class partners, is committed to solving oncology's hardest problems through recent scientific discoveries and advances in drugging various cancer mechanisms.
With initial programs for undisclosed cancer targets already underway, Erasca plans to expand its pipeline through partnerships with academic scientists and biopharmaceutical companies. The firm emphasizes an open-minded approach, not tied to one form of drug or singular treatment strategy, to achieve the greatest results for patients.
